Holocaust survivor Zigi Shipper says he sees Kate Middleton as a friend and claims she s just like a normal young lady .
The Duchess of Cambridge, 39, joined Zigi, 91, and his friend Manfred Goldberg, 90, whom he met as a teenager at the Stutthof concentration camp, for a video call last week.
Kate, who is currently spending lockdown at Anmer Hall with Prince William, 38, and their three children, previously met the two men when she and the Duke visited Stutthof in Poland in 2017.
The trio reconnected during a virtual meeting last Wednesday to mark Holocaust Memorial Day. Speaking to BBC Breakfast this morning, Zigi, who lives in Hertfordshire, said the Duchess made him and Manfred feel very, very comfortable .
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
January 14, 2021 16:05 ET | Source: NextCure NextCure Beltsville, Maryland, UNITED STATES
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
NextCure Provides Updates on NC318 Clinical Program
NextCure Provides Updates on NC318 Clinical Program
BELTSVILLE, Md., Dec. 17, 2020 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.
“As we continue to review and analyze the available clinical and laboratory data on the NC318 program, including recently generated biomarker data, we are working to modify the clinical program to enable us to select S15-positive patients for enrollment in ongoing and future trials,” said Michael Richman, NextCure’s president and chief executive officer. “We remain encouraged regarding the potential of NC318 as a novel oncology treatment, given the evidence of clinical activity seen t